Enveloped vectors for delivering gene therapies
Raised to date
$8.7M
of $8.7M offered across 1 Form D filing
Syenex, Inc. is at the forefront of biotechnology, specializing in advanced delivery technologies for genetic medicine. The company is dedicated to enhancing the field of cell and gene therapy by providing innovative solutions for both in vivo and ex vivo genetic modifications, thereby amplifying the therapeutic potential and clinical impact of these therapies.
Syenex distinguishes itself through its cutting-edge enveloped delivery vector technology, which streamlines complex genetic modifications and partnerships that leverage a hybrid approach combining non-viral and viral methodologies.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jan 27, 2025 | Equity | $8.7M/ $8.7M | Form D |
Delivery Systems
This platform offers a robust solution for genetic medicine applications, focusing on efficient and targeted delivery systems for both ex vivo and in vivo environments. It is designed to overcome the typical barriers in gene therapy such as specificity and efficiency of delivery.
Built for
Genetic medicine developers
